{"id":163909,"date":"2026-11-21T01:21:20","date_gmt":"2026-11-21T01:21:20","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/163909\/"},"modified":"2026-11-21T01:21:20","modified_gmt":"2026-11-21T01:21:20","slug":"is-roche-holding-swxrop-overvalued-after-chmp-backed-gazyva-for-lupus-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/163909\/","title":{"rendered":"Is Roche Holding (SWX:ROP) Overvalued After CHMP Backed Gazyva For Lupus?"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Roche Holding (SWX:ROP) drew fresh attention after Europe&#8217;s CHMP backed Gazyva\/Gazyvaro as an add on treatment for difficult to treat systemic lupus erythematosus, adding another potential autoimmune indication to its portfolio.  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Roche Holding&#8217;s recent autoimmune news lands after a strong run in the share price, with the stock closing at CHF409.3 and posting a 30 day share price return of 7.94% and a year to date share price return of 25.75%. The 1 year total shareholder return of 46.88% points to momentum that has been building rather than fading.  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Scan other healthcare leaders that are benefiting from similar autoimmune and diagnostics catalysts by comparing Roche Holding with a curated set of <a href=\"https:\/\/simplywall.st\/discover\/investing-ideas\/434426\/healthcare-ai\/global?utm_medium=finance_user&amp;utm_campaign=cta_screener_healthcare_ai&amp;utm_source=yahoo&amp;blueprint=4863632\" data-ylk=\"slk:125%20healthcare%20AI%20stocks;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;125 healthcare AI stocks&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">125 healthcare AI stocks<\/a> in just a few minutes.  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Roche Holding now has a fresh autoimmune catalyst layered onto already strong recent shareholder returns. The key tension for investors is simple: Does the current CHF409.3 price still leave room for value?  <\/p>\n<p>        Most Popular Narrative: 7% Overvalued          <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">On Simply Wall St&#8217;s analyst consensus Narrative, Roche Holding&#8217;s fair value of CHF383.96 sits below the last close at CHF409.3. This frames today&#8217;s autoimmune catalyst against a valuation that screens as slightly rich using a 3.95% discount rate.  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Late stage pipeline breadth, including 10 new molecular entities moving into Phase III and the potential launch of up to 19 medicines by the end of the decade, gives Roche multiple shots on goal that can feed new revenue lines and help offset loss of exclusivity impacts on earnings.  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">See why <a href=\"https:\/\/simplywall.st\/narratives\/5ghpcvji-late-stage-pipeline-and-diagnostics-expansion-will-reshape-long-term-prospects?utm_medium=finance_user&amp;utm_campaign=cta_narrative_prompt_after_quote&amp;utm_source=yahoo&amp;blueprint=4863632\" data-ylk=\"slk:20%20investors%20see%20Roche%20Holding%20as%207%25%20overvalued;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;20 investors see Roche Holding as 7% overvalued&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">20 investors see Roche Holding as 7% overvalued<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Result: Fair Value of CHF383.96 (OVERVALUED)  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Still, China&#8217;s 24% Diagnostics sales hit from pricing reform and ongoing loss of exclusivity pressures could quickly challenge the narrative driven by Roche Holding&#8217;s pipeline.  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Find out about the <a href=\"https:\/\/simplywall.st\/company\/id\/04515585-96e8-4172-bae3-19cc35b27fd4?utm_medium=finance_user&amp;utm_campaign=risks_narrative_cta&amp;utm_source=yahoo&amp;blueprint=4863632\" data-ylk=\"slk:key%20risks%20to%20this%20Roche%20Holding%20narrative;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;key risks to this Roche Holding narrative&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">key risks to this Roche Holding narrative<\/a>.  <\/p>\n<p>            Another View On Roche Holding&#8217;s Value          <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Analysts see Roche Holding as 7% overvalued at CHF383.96 fair value, yet our DCF model paints a very different picture. On that cash flow view, the stock trades at roughly a 53.3% discount to an estimated value of CHF876.78. Which lens do you trust when the signals conflict this sharply?  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/simplywall.st\/company\/id\/04515585-96e8-4172-bae3-19cc35b27fd4\/valuation?utm_medium=finance_user&amp;utm_campaign=alternate_dcf_cta&amp;utm_source=yahoo&amp;blueprint=4863632\" data-ylk=\"slk:Look%20into%20how%20the%20SWS%20DCF%20model%20arrives%20at%20its%20fair%20value.;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Look into how the SWS DCF model arrives at its fair value.&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Look into how the SWS DCF model arrives at its fair value.<\/a>  <\/p>\n<p>    <a href=\"https:\/\/simplywall.st\/company\/id\/04515585-96e8-4172-bae3-19cc35b27fd4\/valuation?utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo&amp;blueprint=4863632\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"ROP Discounted Cash Flow as at Nov 2026\" height=\"428\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> ROP Discounted Cash Flow as at Nov 2026           Next Steps          <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Mixed story so far. Roche Holding has clear upside drivers and some real question marks, so consider both perspectives for yourself with 3 key rewards and 1 important warning sign.  <\/p>\n<p>        Looking for more investment ideas beyond Roche Holding?           <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">If Roche Holding has sharpened your appetite for opportunity, do not stop here. Broader context across sectors can help you judge whether this price tag really earns a spot in your portfolio.  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Companies discussed in this article include <a href=\"https:\/\/finance.yahoo.com\/quote\/ROP.SW\" data-ylk=\"slk:ROP.SW;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;ROP.SW&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"nofollow noopener\">ROP.SW<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left tight-spacing neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Have feedback on this article? Concerned about the content? <a href=\"https:\/\/investor-research.typeform.com\/to\/wvg6MFri#feedback_token=NDg2MzYzMjpkYTVkMDA0OGZiNWJiMDI4&amp;company=SWX:ROP&amp;blueprintid=4863632\" data-ylk=\"slk:Get%20in%20touch;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Get in touch&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Get in touch<\/a> with us directly. Alternatively, email <a href=\"https:\/\/finance.yahoo.com\/healthcare\/articles\/mailto:editorial-team@simplywallst.com?subject=Re%3A%20Your%20article%20on%20SWX%3AROP%20(yahoo)%20from%2016th%20November%202026\" data-ylk=\"slk:editorial-team%40simplywallst.com;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;editorial-team@simplywallst.com&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">editorial-team@simplywallst.com<\/a>  <\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding (SWX:ROP) drew fresh attention after Europe&#8217;s CHMP backed Gazyva\/Gazyvaro as an add on treatment for difficult&hellip;\n","protected":false},"author":2,"featured_media":163910,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[159,114,166,39,167,160,161,168,162,163,169,170,171,172,173,174,134,175,164,165,176,177,178,179],"class_list":["post-163909","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-401k","tag-business","tag-business-news","tag-economy","tag-finance","tag-financial-information","tag-investing","tag-investment-tools","tag-investor","tag-market-news","tag-mortgage","tag-mutual-funds","tag-personal-finance","tag-quote","tag-real-estate","tag-retirement","tag-roche","tag-stock","tag-stock-research","tag-stock-valuation","tag-stocks","tag-suze-orman","tag-tax","tag-track-portfolio"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117651812318595165","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/163909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=163909"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/163909\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/163910"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=163909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=163909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=163909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}